Scholarlink

Background <p>The symptomatic and immune responses to COVID-19 vaccination of people with Long COVID are poorly characterized.</p> Methods <p>In this prospective study, we evaluated changes in symptoms and immune responses after COVID-19 vaccination in 16 vaccine-naïve individuals with Long COVID. Surveys were administered before vaccination and at 2, 6, and 12 weeks after receiving the first vaccine dose of the primary series. Simultaneously, SARS-CoV-2-reactive TCR enrichment, SARS-CoV-2-specific antibody responses, antibody responses to other viral and self-antigens, and circulating cytokines were quantified before vaccination and at 6 and 12 weeks after vaccination.</p> Results <p>At 12 weeks post-vaccination, self-reported improved health is seen in 10 out of 16 participants, 3 have no change, and 3 have worse health although 2 report transient improvement after vaccination. One participant reporting worse health was hospitalized twice with chest pain (after each dose). Symptom outcomes are most associated with plasma biosignatures. Higher baseline sIL-6R is associated with symptom improvement, and stably elevated levels of IFN-β and CNTF are associated with no improvement. Significant elevation in SARS-CoV-2-specific TCRs and spike protein-specific IgG are observed at 6 and 12 weeks after vaccination. No changes in reactivities are observed against herpes viruses and self-antigens.</p> Conclusions <p>In this study of 16 people with Long COVID, vaccination is associated with increased SARS-CoV-2 spike protein-specific IgG and T cell expansion in most participants. Specific immune features are associated with symptom change after vaccination and most participants experience improved health or no change following vaccination.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月9日

查看全文
  • Connor B. Grady,
  • Bornali Bhattacharjee,
  • Julio Silva,
  • Jillian Jaycox,
  • Lik Wee Lee,
  • Valter Silva Monteiro,
  • Mitsuaki Sawano,
  • Daisy Massey,
  • César Caraballo,
  • Jeff R. Gehlhausen,
  • Alexandra Tabachnikova,
  • Tianyang Mao,
  • Carolina Lucas,
  • Mario A. Peña-Hernandez,
  • Lan Xu,
  • Tiffany J. Tzeng,
  • Takehiro Takahashi,
  • Jeph Herrin,
  • Diana Berrent Güthe,
  • Athena Akrami,
  • Gina Assaf,
  • Hannah Davis,
  • Karen Harris,
  • Lisa McCorkell,
  • Wade L. Schulz,
  • Daniel Griffin,
  • Hannah Wei,
  • Aaron M. Ring,
  • Leying Guan,
  • Charles Dela Cruz,
  • Harlan M. Krumholz,
  • Akiko Iwasaki

摘要

Background

The symptomatic and immune responses to COVID-19 vaccination of people with Long COVID are poorly characterized.

Methods

In this prospective study, we evaluated changes in symptoms and immune responses after COVID-19 vaccination in 16 vaccine-naïve individuals with Long COVID. Surveys were administered before vaccination and at 2, 6, and 12 weeks after receiving the first vaccine dose of the primary series. Simultaneously, SARS-CoV-2-reactive TCR enrichment, SARS-CoV-2-specific antibody responses, antibody responses to other viral and self-antigens, and circulating cytokines were quantified before vaccination and at 6 and 12 weeks after vaccination.

Results

At 12 weeks post-vaccination, self-reported improved health is seen in 10 out of 16 participants, 3 have no change, and 3 have worse health although 2 report transient improvement after vaccination. One participant reporting worse health was hospitalized twice with chest pain (after each dose). Symptom outcomes are most associated with plasma biosignatures. Higher baseline sIL-6R is associated with symptom improvement, and stably elevated levels of IFN-β and CNTF are associated with no improvement. Significant elevation in SARS-CoV-2-specific TCRs and spike protein-specific IgG are observed at 6 and 12 weeks after vaccination. No changes in reactivities are observed against herpes viruses and self-antigens.

Conclusions

In this study of 16 people with Long COVID, vaccination is associated with increased SARS-CoV-2 spike protein-specific IgG and T cell expansion in most participants. Specific immune features are associated with symptom change after vaccination and most participants experience improved health or no change following vaccination.